2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Adverse Events, Biological Processes, Immune Mechanism, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality Improvement, Diseases, Bleeding and Clotting, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Research, AML, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

5985 Early organ toxicity after allogeneic hematopoietic cell transplantation is multi-organ, non-random, and associated with acute gvhd and non-relapse mortality

Sapir Israeli, PhD, Katya F Ahr, MD, MA2, Amethyst Saldia3, Teng Fei, PhD4, Stephanie Chinapen5, Pamela Susman, MS6, Andrew Harris, MD7, Silvia Escribano Serrat, MD8, Gagan Raju9, Jonathan Peled, MD/PhD10, Mohammad Alhomoud, MD11, Miguel-Angel Perales, MD12, Sergio Giralt, MD13, Sophie Paczesny, MD, PhD14, Roni Shouval Jr, MD, PhD15, Doris M Ponce, MD16
1 Memorial Sloan Kettering Cancer Center, New york, United States
2 Memorial Sloan Kettering Cancer Center, New york, United States
3 Memorial Sloan Kettering Cancer Center, New york, United States
4 Memorial Sloan Kettering Cancer Center, New york, United States
5 Memorial Sloan Kettering Cancer Center, New york, United States
6 Memorial Sloan Kettering Cancer Center, New york, United States
7 Memorial Sloan Kettering Cancer Center, New york, United States
8 Memorial Sloan Kettering Cancer Center, New york, United States
9 Memorial Sloan Kettering Cancer Center, New york, United States
10 Memorial Sloan Kettering Cancer Center, New york, United States
11 Memorial Sloan Kettering Cancer Center, New york, United States
12 Memorial Sloan Kettering Cancer Center, New york, United States
13 Memorial Sloan Kettering Cancer Center, New york, United States
14 Medical University of South Carolina, Charleston, South Carolina, United States
15 Memorial Sloan Kettering Cancer Center, New york, United States
16 Memorial Sloan Kettering Cancer Center, New york, United States

Background: The convergence of conditioning, alloreactivity, infection and drug exposure leads to endothelial activation and mucosal barrier breakdown in the first weeks after allogeneic hematopoietic cell transplantation (alloHCT). This biologic process suggests early organ injury is systemic rather than confined to individual organs, however, toxicity is reported on a per-organ basis. Co-occurrence of early toxicities within patients, their distinct laboratory features including graft-versus-host disease (GVHD) biomarkers and gut microbiome signatures, and their aggregation into a prognostically significant toxicity burden is uncharacterized.

Methods: We analyzed adult and pediatric patients undergoing first alloHCT at a single center (12/2017-1/2026) excluding cord blood grafts under an investigator-initiated non-therapeutic protocol with longitudinal follow-up. Adverse events graded per CTCAE v5 from days -7 to +30 were mapped to 10 composite organ systems. Cumulative burden was defined as the number of affected organ systems (any grade). Pairwise co-occurrence was assessed across all organ pairs using observed-to-expected (O/E) ratios and Fisher exact tests with FDR correction. Peak (nadir for albumin) laboratory values and days +20 to +30 plasma biomarker concentrations (ST2, REG3α) were correlated with maximum organ grade and burden (Spearman). Stool α-diversity was modeled against contemporaneous burden using generalized estimating equations (GEE) adjusted for days relative to HCT. The relationship between burden and grade II-IV acute GVHD (aGVHD), non-relapse mortality (NRM), relapse and overall survival (OS) was examined using day +30 landmark Cox and Fine-Gray models adjusted for age, disease, conditioning intensity, donor type (matched/mismatched; related/unrelated), graft manipulation and GVHD prophylaxis.

Results: We analyzed 163 patients, median age 59 years (range 2-80), 15% age <18; AML 42%, MDS/MPN 20%, other 38%; matched unrelated donor 53%, matched related donor 19%; myeloablative conditioning 55%; peripheral blood graft 87%; GVHD prophylaxis CNI-based 32%, CD34-selected 41%, PTCy-based 27%; median follow-up 43.2 months. Day +100 grade II-IV aGVHD was 52% and 1-year OS, relapse, and NRM were 80%, 14%, and 14%, respectively.

By day +30, 93% of patients had at least 1 organ toxicity of any grade (range 1-4). Gastrointestinal (GI) toxicity was most frequent (n=142, 87%), followed by connective tissue/skin (58%), metabolic/nutritional (47%), neurologic/psychiatric (43%), hematologic/immune (42%), infectious (37%), respiratory (31%), cardiac/vascular (28%), urinary (18%) and hepatobiliary (4%). Median burden was 4 organ systems (IQR 2-6), 77.2% of patients had ≥2 organ system involvement. Organ system co-occurrence was non-random: 30 of 45 organ pairs were enriched beyond chance (FDR<0.05), 13 with O/E ratios ≥1.5. The strongest associations were cardiac-urinary (O/E 2.23) and respiratory-urinary (1.86) systems. In a multivariable regression model, age was the only baseline factor associated with burden (adjusted Incidence Rate Ratios 1.19 per decade, P<0.001).

Organ-specific laboratory signatures were observed. Lower albumin correlated with more severe GI (ρ -0.36), respiratory (-0.31), urinary (-0.30) and hepatobiliary (-0.29) toxicity; higher creatinine with urinary toxicity (0.37), and lower hemoglobin with metabolic toxicity (-0.29); all FDR<0.05. Higher ST2 and REG3α correlated with greater cumulative burden (ρ 0.48, P=0.001 and 0.43, P=0.003). In 57 patients contributing 338 stool samples, lower α-diversity was associated with greater contemporaneous burden (β= -0.02, P=0.02). In multivariable analyses, each additional affected organ was independently associated with increased risk of aGVHD (aHR 1.2, P=0.001), NRM (aHR 1.28, P=0.01) and inferior OS (aHR 1.17, P=0.04). No significant association with relapse was observed.

Conclusion: Multi-organ toxicity is common following allo-HCT and demonstrates non-random patterns of organ co-occurrence suggesting shared biological mechanisms rather than independent organ injury. Distinct organ toxicities are accompanied by characteristic laboratory abnormalities while cumulative organ toxicity burden is associated with reduced microbiome α-diversity and adverse clinical outcomes. Together these findings support the use of early organ toxicity profiling as an integrative marker of HCT-related injury with prognostic relevance beyond individual organ toxicities.
Katya F Ahr, MD, MA: No relevant conflicts of interest to declare.